Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 6:13:961802.
doi: 10.3389/fendo.2022.961802. eCollection 2022.

Non-coding RNAs in diabetes mellitus and diabetic cardiovascular disease

Chengshun Li  1 , Dongxu Wang  1 , Ziping Jiang  2 , Yongjian Gao  3 , Liqun Sun  4 , Rong Li  1 , Minqi Chen  2 , Chao Lin  5 , Dianfeng Liu  1
Affiliations
Review

Non-coding RNAs in diabetes mellitus and diabetic cardiovascular disease

Chengshun Li et al. Front Endocrinol (Lausanne). .

Abstract

More than 10% of the world's population already suffers from varying degrees of diabetes mellitus (DM), but there is still no cure for the disease. Cardiovascular disease (CVD) is one of the most common and dangerous of the many health complications that can be brought on by DM, and has become the leading cause of death in people with diabetes. While research on DM and associated CVD is advancing, the specific mechanisms of their development are still unclear. Given the threat of DM and CVD to humans, the search for new predictive markers and therapeutic ideas is imminent. Non-coding RNAs (ncRNAs) have been a popular subject of research in recent years. Although they do not encode proteins, they play an important role in living organisms, and they can cause disease when their expression is abnormal. Numerous studies have observed aberrant ncRNAs in patients with DM complications, suggesting that they may play an important role in the development of DM and CVD and could potentially act as biomarkers for diagnosis. There is additional evidence that treatment with existing drugs for DM, such as metformin, alters ncRNA expression levels, suggesting that regulation of ncRNA expression may be a key mechanism in future DM treatment. In this review, we assess the role of ncRNAs in the development of DM and CVD, as well as the evidence for ncRNAs as potential therapeutic targets, and make use of bioinformatics to analyze differential ncRNAs with potential functions in DM.

Keywords: cardiovascular disease; circular RNA; diabetes mellitus; long non-coding RNA; microRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Development of T1DM, T2DM, and GDM.
Figure 2
Figure 2
Non-coding RNAs play an important role in diabetes by regulating mRNAs. Red arrows indicate endogenous antibodies and green arrows indicate insulin.
Figure 3
Figure 3
Bioinformatic analysis of the potential role of ncRNAs in DM. KEGG analysis of the target genes of miRNAs up-regulated (A) or down-regulated (B) in T1DM. KEGG analysis of the target genes of differentially expressed miRNAs in T2DM (C). Differential expression of circRNA in T2DM (D). KEGG analysis of the target genes for up-regulated (E) or down-regulated (F) miRNAs in GDM. LncRNAs with altered expression in T2DM patients after metformin treatment (G).
Figure 4
Figure 4
NcRNAs are participating in the development of diabetic CVD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Redondo MJ, Hagopian WA, Oram R, Steck AK, Vehik K, Weedon M, et al. . The clinical consequences of heterogeneity within and between different diabetes types. Diabetologia (2020) 63(10):2040–8. doi: 10.1007/s00125-020-05211-7 - DOI - PMC - PubMed
    1. Eizirik DL, Pasquali L, Cnop M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: Different pathways to failure. Nat Rev Endocrinol (2020) 16(7):349–62. doi: 10.1038/s41574-020-0355-7 - DOI - PubMed
    1. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. . Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci (2020),21(17):6275. doi: 10.3390/ijms21176275 - DOI - PMC - PubMed
    1. Siqueira ISL, Alves Guimarães R, Mamed SN, Santos TAP, Rocha SD, Pagotto V, et al. . Prevalence and risk factors for self-report diabetes mellitus: A population-based study. Int J Environ Res Public Health (2020) 17(18):6497. doi: 10.3390/ijerph17186497 - DOI - PMC - PubMed
    1. Zeru MA, Tesfa E, Mitiku AA, Seyoum A, Bokoro TA. Prevalence and risk factors of type-2 diabetes mellitus in Ethiopia: Systematic review and meta-analysis. Sci Rep (2021) 11(1):21733. doi: 10.1038/s41598-021-01256-9 - DOI - PMC - PubMed

Publication types